Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 17, 2020 06:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

62% 2-year OS; median OS not reachedStable, non-overlapping safety profileClinical synergy between PV-10 and immune checkpoint blockadeData compare favorably to approved therapies for patient...